Oral Contraceptives and Depression-Herzberg et al. Mlsar L 145 different oral contraceptives are to be compared with a control group is in progress and the results will be reported in a later communication.
Introduction
Thyroxine (L-thyroxine) and triiodothyronine (3, 5, are the circulating thyroid hormones in man. Both hormones have been synthesized and each is effective alone in the treatment of hypothyroidism. In contrast to dried thyroid extracts (thyroid B.P., desiccated thyroid U.S.P., thyroglobulin U.S.P.) the composition and potency of triiodothyronine and thyroxine are constant but they differ from each other in physiological action. The dissimilarities of the two hormones are partly due to differences in their binding to protein in both blood and tissues. Thyroxine has a longer biological half-life than triiodothyronine and their effects on laboratory tests of thyroid status differ. The serum protein-bound iodine of patients treated with thyroxine is disproportionately high when compared with their metabolic status and low when triiodothyronine alone is used.
Combinations of synthetic triiodothyronine and thyroxine have been introduced in Britain (Taylor, 1961; Taylor et al., 1970) and the United States (Wool and Selenkow, 1965; Selenkow and Wool, 1967) , and compared with dried thyroid extracts such preparations have the advantage of constant potency. Furthermore, it has been claimed that a 1:4 combination of triiodothyronine and thyroxine mimics the metabolic action of dried thyroid extracts and also produces biochemical values commensurate with the patient's metabolic status (Selenkow and Wool, 1967) . These studies were limited to previously untreated hypothyroid patients and were not adequately controlled. There has been no published report of a valid comparison of combined triiodothyronine and thyroxine with either dried thyroid extract or thyroxine alone, and therefore the present study was undertaken. (Taylor et al., 1970) . All these studies (Selenkow and Wool, 1967; Sachs et al., 1968; Taylor et al., 1970) (Table I) . Analysis of the results in the trial have included independent calculations for each group and dosage because of the imbalance in size and age distribution of the three groups.
The reliability of patients in taking their tablets was similar to that found in other recent studies (Gatley, 1968; Porter, 1969) . Eight patients were excluded from analysis owing to deficiencies of 250, or more in the medication actually taken. Other patients also took fewer tablets than prescribed and a few took more (Table II) but the decision to accept patients with deficiencies of less than 25% was arbitrary; fortunately, the error was similar in both treatment periods. Despite regular attendance at two-monthly intervals during the trial this level of discrepancy between the prescribed and actual dosage emphasizes that the error might be higher with long-term follow-up (Hedley et al., 1970 (Frawley et al., 1956 ) and preparations containing it (Sachs et al., 1968) , and most of them can be attributed to the total dose of the hormone. The total doses of combined triiodothyronine (60 ,jg.) and thyroxine (240 .g.) were higher in this trial for patients taking three tablets daily than in other studies. The incidence of reported symptoms was similar, however, in the two-tablet (14 patients) and three-tablet group (10 patients). Furthermore, these symptoms were not related to intercurrent illnesses, which occurred with equal frequency during therapy with the two preparations.
Nevertheless, the two preparations in this trial differed in their metabolic potency because triiodothyronine has greater biological activity than thyroxine and, consequently, the doses were not equivalent in biological effectiveness. This discrepancy was unavoidable in designing the trial so that patients received the same number of tablets in each period.
About half the patients in this trial were unable to distinguish any difference between the combined tablets and thyroxine alone. Few patients (18 ',,) preferred the combination, and there was a high incidence of unpleasant symptoms reported by other patients during treatment with T,/T, tablets. Many of these patients (24) stated a preference for thyroxine which was almost certainly influenced by the undesirable symptoms probably produced by the triiodothyronine component in the combined preparation. The patient's choice was not related to the sequence of treatment or laboratory tests of thyroid status and was similar in both dosage groups.
The reduction of serum P.B.I. confirms other reports with T,/T, combinations (Wool and Selenkow, 1965; Selenkow and Wool, 1967; Sachs et al., 1968) and reflects the reduction in total dose of thyroxine administered. The alteration in the T3-uptake values was variable (range+9-2% to -10-4%) but not significant. Nevertheless, the "free thyroxine index" (Goolden et al., 1967) (Levy et al., 1964) , but other workers have found normal values on thyroxine (Mitchell et al., 1960; Alley et al., 1968; Goolden, 1969) and with combinations of the two thyroid hormones (Mitchell et al., 1960; Wool and Selenkow, 1965; Selenkow and Wool, 1967; Alley et al., 1968) (Harland and Orr, 1969) . Certainly, clinical assessment is more helpful in MIDICAL JOURNAL adjusting the dosage of thyroid hormones, and the formulation of different ratios of the two hormones to achieve "normal" serum P.B.I. values is pointless if thyroxine alone relieves all the features of hypothyroidism. Thyroxine was well tolerated by patients in this trial, which accords with previous clinical experience, and it can be given conveniently as a single daily dose because it has a long biological half-life. There is no published evidence that patients treated with thyroxine alone suffer any ill effects due to the absence of triiodothyronine.
Fixed-ratio combinations of triiodothyronine and thyroxine cannot be expected to mimic precisely the continuous endogenous secretion of thyroid hormones because the rapid absorption and high biological activity of the triiodothyronine component may produce fluctuations in metabolic activity with untoward symptoms. Other studies have devoted most attention to the effects of combined preparations on laboratory tests, which have limited therapeutic importance in this situation (Harland and Orr, 1969) , and have failed to conduct a valid clinical comparison. The shortcomings of combined therapy deduced from this study suggest that thyroxine has overall advantages for thyroid replacement therapy.
Glaxo Laboratories Ltd. supplied the combined tri-iodothyronine and thyroxin, the thyroxine (Eltroxin), and also the Triosorb
In an earlier paper one of us reported the results of B.C.G. vaccination of 13-year-old Birmingham schoolchildren during 1956-67 (Springett, 1969) . The analysis of results was directed towards the age distribution of the tuberculosis notifications and to detecting any secular trend in the notifications in vaccinated and other groups. It is also possible to analyse the results in terms of periods of vaccination. The object of this paper is to report such a comparison for the periods before and after 16 December, 1961, 
Method
For the purpose of this comparison the following additional data have been extracted from the records: (a) information for a further two years of follow-up (1968 and 1969) and for a further two cohorts of children (aged 13 years last birthday on 31 August in 1967 and in 1968); and (b) a separation of the published follow-up information for the two-year period 1962-3 into the calendar years 1962 and 1963-this permits the follow-up of the earlier cohorts (given liquid vaccine) to be terminated, for the purpose of this study, after about the same duration and over the same range of ages as is now available for the later cohorts (given freeze-dried vaccine).
The basic information has been assembled and the calculations have been performed, in exactly the same way as was done by Springett (1969) . In particular the numbers of unvaccinated tuberculin-negative subjects, and the notifications of tuberculosis among them, were estimated from the figures for all non-participants in the vaccination scheme, (a) by reducing the total number of non-participants by the proportion of particinants who were tuberculin-positive, and (b) by reducing the total cases of tuberculosis among non-participants by the numbers expected (from the known experience of the
